Immuno-Oncology
Toward more predictive preclinical tumor mouse models: conventional tumor models with immunodeficient animals only monitor the effect of a drug on the tumor itself. The approval in 2011 of the first immune-checkpoint inhibitor (Nobel price winner in 2018) has validated the immuno-oncology therapeutic approach against many forms of cancer. The reconstitution of the full functional human immune system in immune-deficient triple KO mice such as NOG/NCG/NSG/BRG provides a unique opportunity to assess the efficacy of new drug candidates acting on both human immune cells such as T cells, myeloid cells and NK cells, and on the tumor itself (bi-specific mAb, ADCC mediation, …) with either Solid (Melanoma, breast, ovarian,…) or Liquid (T-cell lymphoma, B-cell Lymphoma, AML) tumors.
DATA Driven with more than
studies completed
Immune Check Point Inhibitor
- Hu-mouse engrafted with Gastric Tumor Cells
- Treatment with Anti-PD1
- Combo Therapy tested in the same setting
Immune Cell Infiltration
IHC
- Hu-mouse engrafted with Gastric tumor cells
- Immune infiltration (CD8 staining)
Oncolytic Virus Efficacy in hu-mouse
Colon carcinoma. Treatment with oncolytic virus (intra-tumor vs i.v. injection)
Bi-Specific Ab with ADCC activity
- Hu-mouse engrafted with HCT-116 colorectal cancer cells
- Treatment with Bi-specific Ab
- ADCC activity
T Cell Immunity – Vaccination
- Hu-mouse vaccinated against Mart-1 peptide
- Cellular response in the peripheral blood 28 days after vaccination
- Tetramer Staining of CD8+ cells
Transient Boost with human Cytokines

Strength of TransCure bioServices in cancer/immuno-Oncology/PDX
- >3’000 hu-mouse tested for cancer/immuno-oncology/PDX
- Human cytokine boosts available upon request
- Validated models for: immune checkpoint inhibitors, PDX, oncolytic viruses, ADCC, vaccines
- Ideal for combination strategy
- Expertise in protocol/study design/endpoints with hu-mouse
- Quality raw data collection and report analysis
- Time and cost-saving, competitive FTE rate
Find out about our Disease Models:
Cancer/Immuno-oncology/PDX -- Infection-HIV -- Inflammation - IBD -- Vaccine - Immunization -- GvHD -- Hu-liver -- Asthma